Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
1.54
Dollar change
-0.05
Percentage change
-3.14
%
Index- P/E- EPS (ttm)-2.44 Insider Own2.52% Shs Outstand13.42M Perf Week-2.53%
Market Cap20.67M Forward P/E- EPS next Y-1.30 Insider Trans23.79% Shs Float13.08M Perf Month20.31%
Income-31.10M PEG- EPS next Q-0.88 Inst Own8.49% Short Float9.23% Perf Quarter-20.21%
Sales0.00M P/S- EPS this Y11.24% Inst Trans-14.30% Short Ratio2.00 Perf Half Y129.89%
Book/sh0.26 P/B5.85 EPS next Y56.67% ROA-55.89% Short Interest1.21M Perf Year62.11%
Cash/sh2.67 P/C0.58 EPS next 5Y- ROE-172.86% 52W Range0.62 - 2.50 Perf YTD-21.83%
Dividend Est.- P/FCF- EPS past 5Y-11.51% ROI-133.29% 52W High-38.40% Beta2.36
Dividend TTM- Quick Ratio2.35 Sales past 5Y-48.94% Gross Margin- 52W Low147.59% ATR (14)0.12
Dividend Ex-Date- Current Ratio2.35 EPS Y/Y TTM31.56% Oper. Margin0.00% RSI (14)50.48 Volatility5.07% 7.08%
Employees14 Debt/Eq5.89 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price6.50
Option/ShortNo / Yes LT Debt/Eq5.80 EPS Q/Q87.51% Payout- Rel Volume0.37 Prev Close1.59
Sales Surprise- EPS Surprise13.37% Sales Q/Q- EarningsMar 28 BMO Avg Volume604.49K Price1.54
SMA202.48% SMA50-0.93% SMA20022.91% Trades Volume225,397 Change-3.14%
Date Action Analyst Rating Change Price Target Change
May-28-21Upgrade Gabelli & Co Sell → Hold
Mar-15-21Upgrade H.C. Wainwright Neutral → Buy $2.50
Jun-02-20Downgrade RBC Capital Mkts Outperform → Sector Perform $7 → $2
Jan-21-20Downgrade Gabelli & Co Buy → Sell
Dec-11-19Downgrade SVB Leerink Outperform → Mkt Perform
Jun-21-19Initiated H.C. Wainwright Buy $17
Today 11:53AM
07:00AM
Mar-21-24 04:30PM
Mar-15-24 08:00AM
Mar-07-24 07:57AM
08:00AM Loading…
Mar-06-24 08:00AM
Feb-01-24 03:03PM
Jan-30-24 07:00AM
Dec-04-23 08:00AM
Nov-15-23 12:22PM
12:08AM
Nov-14-23 07:00AM
Nov-07-23 08:30AM
Oct-24-23 08:00AM
Oct-12-23 09:15AM
10:10PM Loading…
Aug-11-23 10:10PM
07:00AM
Aug-04-23 05:00PM
Jun-27-23 09:50AM
Jun-21-23 08:35AM
Jun-12-23 06:23PM
May-12-23 07:00AM
May-10-23 09:16AM
Apr-20-23 05:00PM
Apr-13-23 12:00PM
Mar-18-23 02:06AM
Mar-16-23 09:16PM
07:00AM
Mar-09-23 05:00PM
Jan-11-23 06:00PM
08:00AM Loading…
Dec-15-22 08:00AM
Nov-10-22 07:00AM
Nov-03-22 08:00AM
Oct-20-22 07:30AM
Oct-17-22 05:19PM
Sep-19-22 07:30AM
Sep-07-22 09:15AM
Sep-01-22 04:15PM
Aug-17-22 09:45AM
Aug-16-22 09:00PM
Aug-12-22 07:00AM
Jul-11-22 02:31PM
07:30AM
Jul-06-22 04:30PM
Jun-14-22 05:00PM
May-13-22 07:00AM
May-11-22 08:00AM
Apr-25-22 05:06PM
Mar-28-22 10:19AM
07:00AM
Mar-21-22 08:00AM
Mar-10-22 08:00AM
Feb-08-22 05:00PM
Dec-14-21 04:30PM
07:12AM
Dec-13-21 08:00AM
Nov-22-21 10:00AM
Nov-12-21 07:00AM
Nov-05-21 07:00AM
Oct-04-21 02:58PM
01:28PM
12:33PM
11:05AM
10:45AM
10:00AM
09:40AM
08:36AM
07:30AM
05:34AM
Oct-03-21 07:55PM
10:20AM
10:00AM
Oct-01-21 07:00PM
03:45PM
03:09PM
11:30AM
11:00AM
09:13AM
07:45AM
07:00AM
05:22AM
Sep-30-21 11:05PM
11:45AM
11:00AM
09:00AM
08:10AM
08:00AM
05:21AM
Sep-29-21 08:40PM
08:05PM
01:00PM
12:20PM
09:20AM
08:30AM
07:03AM
Sep-28-21 06:29PM
04:50PM
04:05PM
03:50PM
02:00PM
Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dunne Michael W.DirectorDec 22 '23Buy1.4025,00035,000113,754Dec 27 09:00 AM
Dunne Michael W.DirectorDec 18 '23Buy1.8410,00018,44288,754Dec 19 04:15 PM
Dunne Michael W.DirectorNov 22 '23Buy2.0320,00040,69078,754Nov 27 05:00 PM
Fishman Corey N.Chief Executive OfficerNov 20 '23Buy1.5910,00015,86354,449Nov 20 05:00 PM
Hecht BethDirectorJun 15 '23Option Exercise0.0015,853018,839Jun 15 05:00 PM
Chin MarkDirectorJun 15 '23Option Exercise0.0015,853018,306Jun 15 05:00 PM
Dunne Michael W.DirectorJun 15 '23Option Exercise0.0015,853053,488Jun 15 05:00 PM
Dunne Michael W.DirectorApr 01 '23Option Exercise0.001,299037,636Apr 03 08:00 PM
HUNT RONALDDirectorApr 01 '23Option Exercise0.002,04106,071Apr 03 08:00 PM